Tech Company Financing Transactions
WaVe Life Sciences Funding Round
On 8/18/2015, WaVe Life Sciences landed $66 million in Series B investment from Foresite Capital, Cormorant Asset Management and Fidelity Management & Research Company.
Transaction Overview
Company Name
Announced On
8/18/2015
Transaction Type
Venture Equity
Amount
$66,000,000
Round
Series B
Investors
Proceeds Purpose
WAVE expects to use the proceeds from the Series B financing to continue to evolve its chemistry platform and advance a broad pipeline of stereopure nucleic acid therapeutics, including candidates for Huntington's disease and Duchenne muscular dystrophy, across a breadth of oligonucleotide modalities, including RNAi, antisense and exon-skipping, among others. The company plans to file its first INDs by the end of 2016.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
733 Concord Ave.
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
WaVe Life Sciences (NASDAQ: WVE) is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/18/2015: Pacific Ag Systems venture capital transaction
Next: 8/18/2015: Helix venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs